PIK3C3 and cancer: MPT0L145, an alleged dual-target inhibitor of PIK3C3 and FGFR, not only increased autophagosome formation due to FGFR inhibition but also interfered with autophagic flux via PIK3C3 inhibition, It synergistically sensitized anticancer effects of targeted- or chemo-therapy in different cancer cell lines (Chen et al., 2018).